Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Protara Therapeutics, Inc. (TARA)

Protara Therapeutics: Chief Medical Officer Leonardo Nicacio resigns, effective June 26

Neutral Impact 3 of 5 leadership Written later

Protara Therapeutics said its Chief Medical Officer, Leonardo Viana Nicacio, M.D., resigned to explore other opportunities, effective June 26, 2026. His duties will be taken over by Carla Beckham, M.D., and will continue under the oversight of Jacqueline Zummo, Ph.D., the company's Chief Research & Development Officer.

Key points

  • Leonardo Viana Nicacio, M.D., Chief Medical Officer, resigned effective June 26, 2026, to explore other opportunities
  • Carla Beckham, M.D., Lead Medical Director and Head of Clinical Development, will assume Dr. Nicacio's duties
  • Jacqueline Zummo, Ph.D., Chief Research & Development Officer, will oversee the work

The filing

CompanyProtara Therapeutics, Inc. (TARA)
Form8-K, current report
Filed with the SECJun 29, 2026, 5:02 PM ET
Accession number0001213900-26-073184

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.